asianprimenews
Breaking News
Breaking NewsGeneralPublic Interest

ELGi Introduces Air~Alert in India – Smart Monitoring and Alert System for Compressed Air Systems

by asianprimenews0781

Coimbatore, 13 September 2023: Elgi Equipments Limited, one of the world’s leading air compressor manufacturers, announced today the introduction of Air~Alert, an IoT-based Air Compressor Monitoring System, for the Indian market. After a successful launch at the Hannover Messe in Germany earlier this year, the ELGi Air~Alert smart 24/7 remote monitoring and alert system is now available to ELGi’s customers in India for new and existing installations*.

Air~Alert is a data transmission and analysis service that monitors critical parameters and sends out actionable insights and alerts to users. With these insights, customers can improve uptime and maximise efficiency with smart monitoring and data related to air compressor performance. The service also enables customers to act in time and avoid potential failures. Additionally, Air~Alert enables 24/7 remote monitoring of the air compressor. It delivers trend graphs and information about operating parameters, including discharge pressure, oil temperature, variable frequency drive (VFD) speed (where fitted), total running hours, trips, and alerts on a live online interface accessible remotely from anywhere in the world.

Air~Alert also notifies customers and ELGi channel partners about scheduled maintenance and fault occurrences while predicting commonly occurring failures. Monthly summary reports on overall health and operating parameters, including upcoming service requirements and preventative maintenance based on the data obtained, are sent to customers.

The operational and performance data from the compressors are acquired by Air~Alert from the compressor controller, transmitted in an encrypted form, and sent to secure and dedicated Air~Alert servers in the cloud. Smart algorithms then work on the data to enable intelligent prediction with actionable alerts, reports, and trends – which are returned securely to the operators as easy-to-read actionable dashboards.

Throughout the process, the data is structured and analysed to provide smart analysis that helps users to plan maintenance activities, enabling energy efficiency improvements with the compressor. The Air~Alert failure prediction module also predicts if the compressor is likely to fail in the future. At the end of the process, data is translated into comprehensible alerts and reports that allow the user to take timely action.
With ELGi’s Air~Alert, users can track highly informative utilisation trends providing actionable intelligence and take corrective actions, such as:
• Operating pressure band optimisation based on the utilisation rate
• Replacing an existing fixed speed unit with a variable speed VFD unit/ or adding a retrofit VFD
• Providing an energy efficient, lower size compressor in case of very low utilisation rate
• Detecting leaks based on an unexpected change to a higher utilisation rate over time
*The Air~Alert device can be factory-fitted on new ELGi EG, AB, and OF Series compressors or retrofitted on units with a Neuron III, III+, or IV controller.
 
About ELGi: Elgi Equipments Limited is a global air compressor manufacturer with a broad line of innovative and technologically superior compressed air systems. ELGi has consistently worked towards ensuring that its customers achieve their productivity goals while keeping the cost of ownership low. ELGi offers a complete range of compressed air solutions from oil lubricated and oil free rotary screw compressors, oil lubricated and oil free reciprocating compressors and centrifugal compressors, to dryers, filters and downstream accessories. The company’s portfolio of over 400 products has found wide application across industries. For further information on the organisation and its products, please visit http://www.elgi.com
—————————————————————————————

Facebook

Twitter

LinkedIn

YouTube

Instagram

Media Contacts
ELGi
Anya Geraldine D’Souza
Vice President, Global Marketing
anya@elgi.com

Balamurugan. K
Manager – Marketing and Corporate Communications
bala.kalaimani@elgi.com

Weber Shandwick

Pratvii Ponnappa
Account Director
PPonnappa@webershandwick.com

Rajarshi Bhattacharjee
Project Manager
RBhattacharjee@webershandwick.com

Share

Related posts

Bigg Boss OTT House follows the world of fantasy!

asianprimenews

Why CML Isn’t a Solved Disease—And What Patients in India Need to Know* Over the past two decades, Chronic Myeloid Leukemia (CML) has undergone a transformation—from being a life-threatening condition to one that can be controlled with oral medication. Although survival rates have improved significantly, the idea of CML as a ‘manageable’ disease is now being questioned. Clinicians and patients alike are recognizing that the existing standard of care does not address the full picture—especially for India’s younger patient population, whose needs go far beyond survival. Dr Subhaprakash Sanyal Director of Haematology and BMT Services, Fortis Hospital, Mumbai, said, “There’s a common belief that starting treatment for CML means the journey is simple, but that isn’t the case. Many patients struggle to reach their treatment milestones as expected, and a significant portion need to change or stop their medication due to side effects or intolerance. In fact, about 30 to 40% discontinue their initial therapy within five years, highlighting that the standard approach doesn’t work for everyone.” CML disproportionately affects younger adults in India, where the median age of diagnosis is between 35 and 40 years—much younger than the average age of 50–60 in Western countries. At this life stage, patients are often building careers, supporting families, and planning long-term futures. In this context, treatment is no longer just about survival—it’s about maintaining energy, emotional well-being, professional productivity, and daily independence. Historically, the primary treatment goal in CML was achieving Major Molecular Response (MMR). But over the years, these goals have evolved. Today, physicians aim for deeper responses, particularly Deep Molecular Response (DMR). Achieving DMR paves the way for Treatment-Free Remission (TFR), where patients can potentially stop therapy altogether and remain in remission under medical supervision. These advanced milestones are particularly relevant to newly diagnosed patients, as reaching DMR within the first two years greatly improves the likelihood of achieving TFR down the line. Why So Many Patients Fall Short Despite clear treatment goals, a significant proportion fail to achieve MMR within the first year, and even fewer reach DMR by year two. One of the primary reasons is the impact of persistent, low-grade side effects—such as fatigue, joint pain, and gastrointestinal issues—which patients often tolerate silently but which meaningfully reduce their quality of life. These side effects also drive nonadherence, dose modifications, and ultimately treatment discontinuation. In fact, treatment intolerance is the leading cause of therapy discontinuation in the first two years of CML management. Adding to the complexity, current treatments—particularly ATP-competitive tyrosine kinase inhibitors (TKIs)—can affect not just the intended target but also unrelated biological pathways, causing off-target toxicity. This often leads to therapy switches, a strategy that increases both clinical and emotional burden without necessarily resolving the issue. A recent Indian analysis noted that nearly all CML patients report some form of low-grade side effect, many of which disrupt work and personal life but don’t qualify for hospitalization. As a result, patients feel caught in a difficult balance—managing a chronic illness while enduring ongoing discomfort or disruptions. The Case for Better-Tolerated, More Effective Therapies As the treatment landscape evolves, the need for therapies that not only offer deeper molecular responses but also better tolerability is becoming increasingly clear. Emerging therapies with novel mechanisms of action have begun to change the paradigm by offering comparable—or even superior—efficacy alongside fewer adverse events and lower discontinuation rates. In one international phase III trial, a newer therapy demonstrated a 74.1% MMR rate at 96 weeks, significantly higher than the 52.0% achieved by older therapies. It also showed a 54% lower risk of treatment discontinuation due to side effects, while nearly half of patients achieved MR4 and 30.9% achieved MR4.5, the deepest levels of response. These findings suggest that treatment no longer needs to be a trade-off between efficacy and day-to-day functioning. This shift is particularly important in the Indian context, where younger patients face the possibility of decades-long treatment. For them, the ability to tolerate therapy comfortably while still achieving long-term disease control is not a luxury—it’s a necessity. The Importance of Proactive Conversations Many patients continue older treatments unaware that newer, more tolerable options exist. This makes open doctor–patient conversations crucial—especially early in treatment. Patients should understand their goals, like DMR or TFR, and how their therapy aligns with them. Discussing side effects, lifestyle impact, and alternatives helps ensure care is not just effective, but sustainable and suited to their lives. While CML outcomes have improved, challenges remain—particularly for India’s younger patients. As treatment goals expand and better options emerge, the focus must shift from merely managing the disease to helping patients live well. The future of CML care lies in deeper responses, better tolerability, and enabling life beyond medication.

asianprimenews

KidZania India partners with Bandhan Bank to bring the Banking Role-Play Experience for the young learners

asianprimenews